Literature DB >> 26680256

Dilated cardiomyopathy following use of xenadrine EFX.

Graziano Riccioni1, Giuseppe Speziale2, Luca Scotti3, Valentina Bucciarelli3, Silvia Cappetti4, Giuseppe Nasso2, Sabina Gallina5, Tonino Bucciarelli3.   

Abstract

We describe a case of a 35-year-old man presented at the emergency room of our institution with acute onset of dyspnea and dizziness. He was a body builder and had been using Xenadrine EFX for weight loss reduction. The laboratory analyses were normal. A chest radiograph showed an enlarged cardiac silhouette with clear lung fields. Transtoracic two-dimensional color Doppler echocardiography revealed a diffuse hypokinesia with a marked decreased in systolic function and a high teledyastolic diameter. This case document the possible relation to use of Xenadrine EFX for weight loss and the recurrence of dilated cardiomyopathy.
© The Author(s) 2015.

Entities:  

Keywords:  dilated cardiomyopathy; weight loss; xenadrine

Mesh:

Substances:

Year:  2015        PMID: 26680256      PMCID: PMC5806743          DOI: 10.1177/0394632015599701

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  5 in total

1.  Coronary thrombosis related to use of Xenadrine RFA.

Authors:  Rajesh Sachdeva; Satish Sivasankaran; Robert F Fishman; Stuart W Zarich; Craig A McPherson
Journal:  Tex Heart Inst J       Date:  2005

2.  Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine.

Authors:  David Samenuk; Mark S Link; Munther K Homoud; Robert Contreras; Theoharis C Theoharides; Paul J Wang; N A Mark Estes; Theoharis C Theohardes
Journal:  Mayo Clin Proc       Date:  2002-01       Impact factor: 7.616

3.  Hemodynamic effects of ephedra-free weight-loss supplements in humans.

Authors:  Christine A Haller; Neal L Benowitz; Peyton Jacob
Journal:  Am J Med       Date:  2005-09       Impact factor: 4.965

4.  Coronary artery aneurysm and thrombosis following chronic ephedra use.

Authors:  Casey M Flanagan; Julie L Kaesberg; Eric S Mitchell; Michael A Ferguson; Mark C P Haigney
Journal:  Int J Cardiol       Date:  2008-08-20       Impact factor: 4.164

5.  Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.

Authors:  C A Haller; N L Benowitz
Journal:  N Engl J Med       Date:  2000-12-21       Impact factor: 176.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.